Research & Development
Vanda Pharmaceuticals' VTR-297 IND application receives US FDA approval
1 February 2024 -

Biopharmaceutical company Vanda Pharmaceuticals Inc (Nasdaq:VNDA) announced on Wednesday that it has received approval from the US Food and Drug Administration (FDA) for the Investigational New Drug (IND) application to assess VTR-297 intended for the treatment of onychomycosis, a fungal infection of the nail.

VTR-297 is a small molecule histone deacetylase (HDAC) inhibitor with activity against dermatophytes and fungi, originally isolated from the yeast species Streptomyces hygroscopicus as an antifungal antibiotic, first described in 1976.

Mihael H Polymeropoulos, MD, Vanda's president, CEO and chairman of the board, said: "The initiation of clinical studies with VTR-297 in the treatment of onychomycosis is an important milestone in studying and developing potential new therapies for this common disorder."